Q2 FY2026 · ended Jun 30, 2026 · Revenue $15.60M, +43.1% YoY · Filed Aug 13, 2026
Pelthos Therapeutics Inc. (PTHS) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $15.6 million and a net loss of $23.4 million. Free cash flow was -$7.7 million. As of Jun 30, 2026 it held $24.2 million in cash and investments and $3.2 million in total debt.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PTHS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Durham, NC
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1919246
- Former names
- Channel Therapeutics Corp (until May 27, 2025); Chromocell Therapeutics Corp (until Nov 15, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $15.6M | $10.9M | $16.5M | $294,000 | — |
| Operating income | -$17.3M | -$13.1M | -$12.0M | -$15.4M | -$3.2M |
| Net income | -$23.4M | -$25.1M | -$21.7M | -$16.2M | -$3.4M |
| Diluted EPS | -$6.62 | -$7.57 | -$6.85 | -$5.30 | -$5.29 |
| Operating cash flow | -$7.7M | -$13.1M | -$6.3M | -$15.3M | -$447,000 |
| Free cash flow | -$7.7M | -$13.3M | — | — | — |
| Total assets | $137.4M | $145.4M | $130.4M | $126.4M | $822,850 |
| Total liabilities | $138.9M | $126.1M | $91.5M | $68.2M | $7.3M |
| Stockholders' equity | -$1.5M | $19.3M | $38.9M | $58.3M | -$6.5M |
| Cash and investments | $24.2M | $32.0M | $18.0M | $14.2M | $59,000 |
| Total debt | $3.2M | $3.3M | $3.4M | $2.8M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Change to shareholder rights, Officer or director change, Bylaw or fiscal year change, Shareholder vote results, Regulation FD disclosure
|
Oct 30, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Oct 1, 2026 | Sep 29, 2026 |
| ARS | Annual report to shareholders | Aug 18, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q/A | Amended quarterly report | Aug 13, 2026 | Mar 31, 2026 |
All 253 Pelthos Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.